Aditxt, Inc. entered into a merger agreement with Evofem Biosciences, Inc., with Evofem surviving as a wholly owned subsidiary of Aditxt. Evofem shareholders will receive $1.8 million in exchange for their common stock and their preferred stock will be converted into Aditxt preferred stock. The merger is subject to certain conditions and approvals.